Text Size

Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery

This study has been completed.
Sponsor:
Information provided by:
University of Oslo School of Pharmacy
ClinicalTrials.gov Identifier:
NCT00244530
First received: October 25, 2005
Last updated: December 20, 2006
Last verified: December 2006
History of Changes
  Purpose

To compare renal function (51Cr-EDTA clearance) 48 hours post open-heart surgery (coronary bypass or valve surgery) in patients with impaired renal function after randomization to either nifedipine infusion at start of surgery and the following 24 hours or placebo (0.9% saline infusion). Study hypothesis is that nifedipine has a prophylactic effect on decline in renal function.


Condition Intervention Phase
Kidney Failure, Chronic
Coronary Artery Disease
 Drug: Nifedipine
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Postoperative Renal Function After Open-Heart Surgery in Patients With Impaired Renal Function Preoperatively. A Study of the Calcium Channel Blocker Nifedipine's Prophylactic Effect on Further Decline in Renal Function.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Oslo School of Pharmacy:

Primary Outcome Measures:
  • Primary efficacy endpoint is change in renal function, evaluated by 51Cr-EDTA clearance between 24 hours pre open-heart surgery and 48 hours post open-heart surgery. Sample size is 20, ten in each group.

Secondary Outcome Measures:
  • Change in renal function after open-heart surgery, as measured by cimetidine refined serum creatinine clearance with measurements preoperatively and 2–6 hours, 20–24 hours and 44–48 hours postoperatively. Need for dialysis post-operatively.

Estimated Enrollment: 20
Study Start Date: June 2001
Estimated Study Completion Date: October 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients of either gender above 18 years of age.
  2. Patients with significant coronary stenosi(e)s (≥ 75% coronary artery lumen surface stenosi(e)s and / or aortic- or mitral valve vitriuim that are accepted for coronary artery bypass surgery and/or valve replacement surgery.
  3. Patients with impaired renal function, defined as increased serum- creatinine. Men: ≥ 150 µmol/l and Women: ≥130 µmol/l.

Exclusion Criteria:

  1. Patients on maintenance hemodialysis
  2. Renal transplant patients
  3. Patients with ejection fraction ≤ 35%
  4. Patients with unstable angina pectoris
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00244530

Locations
Norway
Rikshospitalet University Hospital
Oslo, Norway, 0027
Sponsors and Collaborators
University of Oslo School of Pharmacy
Investigators
Study Chair: Jan F Bugge, MD, PhD Rikshospitalet University Hospital, Oslo, Norway
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00244530     History of Changes
Other Study ID Numbers: NIF-123
Study First Received: October 25, 2005
Last Updated: December 20, 2006
Health Authority: Norway: Directorate of Health

Keywords provided by University of Oslo School of Pharmacy:
Preventive Therapy
Calcium Channel Blockers
Kidney Failure, Chronic
Coronary Artery Bypass
Heart Valve Prosthesis Implantation

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Kidney Failure, Chronic
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Renal Insufficiency, Chronic
Kidney Diseases
 Urologic Diseases
Calcium Channel Blockers
Nifedipine
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs
Vasodilator Agents

ClinicalTrials.gov processed this record on May 19, 2013